Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Int J Antimicrob Agents ; 28(5): 472-6, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17046209

ABSTRACT

A national multicentre prevalence study was undertaken to determine the bacterial strains associated with mild-to-moderate acute exacerbations of chronic bronchitis (AECB) in the primary care setting and the susceptibility of isolated pathogens to different antimicrobials usually prescribed to these patients. All samples were processed by a central reference laboratory. Microdilution tests were carried out to establish the minimum inhibitory concentration (MIC) of various antimicrobials. A double-disk test was performed to establish the macrolide resistance phenotype in Streptococcus pneumoniae. Tests to detect the presence of beta-lactamase in Haemophilus influenzae and Moraxella catarrhalis and polymerase chain reaction to detect the presence of ermB and mefA genes in S. pneumoniae isolates were also performed. A total of 1537 patients were included in the trial and 468 microorganisms were isolated from sputum samples, with the most frequent isolates being S. pneumoniae (34.8%), M. catarrhalis (23.9%) and H. influenzae (12.6%). Resistance rates of pneumococci were 47.2% for penicillin, 1.2% for amoxicillin, 34.3% for macrolides (87.5% of which showed high-level resistance), 13.6% for cefuroxime/axetil and 4.2% for levofloxacin. No bacterial isolates showed resistance to telithromycin. Empirical antibiotic treatment was prescribed to 98.3% of patients, including macrolides to 36.6%, amoxicillin with or without clavulanic acid to 32.3% and fluoroquinolones to 16.1%. In conclusion, S. pneumoniae was the most frequently isolated bacteria in patients with mild-to-moderate AECB. Despite the high rates of resistance of pneumococci to macrolides, they continue to be the most widely used antibiotics in primary care to treat AECB.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bronchitis, Chronic/drug therapy , Drug Resistance, Bacterial/genetics , Sputum/microbiology , Adult , Aged , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Bronchitis, Chronic/epidemiology , Bronchitis, Chronic/microbiology , Cross-Sectional Studies , Female , Haemophilus influenzae/drug effects , Haemophilus influenzae/genetics , Haemophilus influenzae/isolation & purification , Humans , Male , Membrane Proteins/genetics , Methyltransferases/genetics , Microbial Sensitivity Tests , Middle Aged , Moraxella catarrhalis/drug effects , Moraxella catarrhalis/genetics , Moraxella catarrhalis/isolation & purification , Prevalence , Primary Health Care/statistics & numerical data , Spain/epidemiology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/isolation & purification
2.
Rev Clin Esp ; 190(3): 134-6, 1992 Feb.
Article in Spanish | MEDLINE | ID: mdl-1561456

ABSTRACT

We present two cases of visceral leishmaniasis in patients with AIDS which represent two different clinical patterns of the disease. Special emphasis is made on the need to lavish bone marrow studies in those patients with AIDS who present fever of unknown origin since immunodepression can modify the classical clinical picture of the disease. According to our experience, visceral leishmaniasis should be included amongst the infections indicative of AIDS in patients with HIV infection.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Leishmaniasis, Visceral/diagnosis , Adult , Antimony/therapeutic use , Bone Marrow Examination , Female , Fever of Unknown Origin/diagnosis , Humans , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/etiology , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...